Second Phase 3 Caplyta bipolar mania trial meets endpoints
FROM THE WIRE · FINANCE.YAHOO.COM
Johnson & Johnson reported that its second pivotal Phase 3 trial of Caplyta in bipolar I mania met primary and key secondary endpoints, with clinically meaningful improvements in manic symptoms versus placebo, supporting a planned U.S. regulatory filing. The readout strengthens…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe success strengthens Johnson & Johnson's neuroscience pipeline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The second Phase 3 trial of Caplyta in bipolar I mania met primary endpoints.
- 02Johnson & Johnson plans a U.S. regulatory filing.
- 03Fresh blood cancer data are also expected.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets